Phio PharmaceuticalsPHIO
13F holders, Q2 2025 (June 30)11holders
4new positions
4sold out
$2.35avg. 13F price*
At the end of Q2 2025, 11 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings, unchanged from Q1 2025. 4 opened new positions and 4 sold out. The largest holders were Geode Capital Management, LLC ($136K), Vanguard Group Inc. ($114K) and Cetera Investment Advisers ($76K).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $156K |
| Exits | 4 | $17K |
All 13F filers, Q1 2025 → Q2 2025: 83,508 shares bought and 19,409 shares sold, net +64,099 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | Add +38.7% | 57,694 | $136K |
| Vanguard Group Inc. | 0.00% | New | 48,665 | $114K |
| Cetera Investment Advisers | 0.00% | Reduce -15.6% | 32,500 | $76K |
| Virtu Financial LLC | 0.00% | New | 14,298 | $34K |
| Morgan Stanley | 0.00% | No change | 6,000 | $14K |
| Royal Bank of Canada | 0.00% | New | 3,464 | $8K |
| SBI Securities Co., Ltd. | 0.00% | Add +97.2% | 1,909 | $4K |
| Assetmark, Inc. | 0.00% | No change | 110 | $259 |
| Bank of America Corp. | 0.00% | Add +12.2% | 46 | $108 |
| Elevation Point Wealth Partners, LLC | 0.00% | New | 27 | $63 |
| Activest Wealth Management | 0.00% | No change | 9 | $21 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.